This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.This study represents a novel clinical trial strategy designed to assess both prospective 'prophylactic' therapy for psychopathology in AD and also to assess an approach that may alter several aspects of the pathophysiology of AD, thereby perhaps resulting in neuroprotective effects, which would be assessed by monitoring clinical progression of illness as well as relevant biomarkers and imaging data.The primary objective of this study is to demonstrate in a randomized, placebo-controlled clinical trial whether chronic valproate therapy delays the emergence of agitation and/or psychosis in outpatients with probable Alzheimer's disease (AD) who have not yet experienced agitation or psychosis during the course of their illness. The chief secondary aim is to determine whether chronic valproate therapy for up to two years delays the progression of cognitive, functional, other behavioral, and global measures of illness. We hypothesize that active therapy will result in slowing of decline in these measures.Other secondary aims: The study will address the tolerability and safety of low-dose, long-term valproate therapy versus placebo by the assessment of adverse experiences, comorbid events, vital signs, and laboratory measures. We hypothesize that active treatment will be well tolerated. We will measure possible drug-placebo differences in quality of life. We hypothesize that active treatment will be associated with higher quality of life ratings. We will study biological markers selected for their possible relevance to the pathophysiology of Alzheimer's disease, as well as the postulated mechanism of action of valproate. We will conduct repeated MRI scans in a subset of patients enrolled to assess whether there may be possible drug-placebo differences in brain volumetric measurements. (Note that our UCI site will not participate in this MRI substudy). We hypothesize that specific valproate-mediated biochemical alterations will correlate with clinical and structural imaging responses. Finally, we will examine the effects of withdrawal of active treatment vs placebo treatment after two years of treatment. We hypothesize that withdrawal of active vs placebo treatment will not yield differences in change in behavioral, cognitive, functional, or global measures of disease from month 24 to month 26.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000827-32
Application #
7606624
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
2006-12-01
Project End
2007-11-30
Budget Start
2006-12-01
Budget End
2007-11-30
Support Year
32
Fiscal Year
2007
Total Cost
$2,326
Indirect Cost
Name
University of California San Diego
Department
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Lavigne, Katie M; Woodward, Todd S (2018) Hallucination- and speech-specific hypercoupling in frontotemporal auditory and language networks in schizophrenia using combined task-based fMRI data: An fBIRN study. Hum Brain Mapp 39:1582-1595
Milot, Marie-Hélène; Marchal-Crespo, Laura; Beaulieu, Louis-David et al. (2018) Neural circuits activated by error amplification and haptic guidance training techniques during performance of a timing-based motor task by healthy individuals. Exp Brain Res 236:3085-3099
Hsu, Simon; Rifkin, Dena E; Criqui, Michael H et al. (2018) Relationship of femoral artery ultrasound measures of atherosclerosis with chronic kidney disease. J Vasc Surg 67:1855-1863.e1
Inker, Lesley A; Grams, Morgan E; Levey, Andrew S et al. (2018) Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium. Am J Kidney Dis :
Egnot, Natalie Suder; Barinas-Mitchell, Emma; Criqui, Michael H et al. (2018) An exploratory factor analysis of inflammatory and coagulation markers associated with femoral artery atherosclerosis in the San Diego Population Study. Thromb Res 164:9-14
Juraschek, Stephen P; Miller 3rd, Edgar R; Appel, Lawrence J (2018) Orthostatic Hypotension and Symptoms in the AASK Trial. Am J Hypertens 31:665-671
Grams, Morgan E; Sang, Yingying; Ballew, Shoshana H et al. (2018) Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate. Kidney Int 93:1442-1451
Chen, Teresa K; Appel, Lawrence J; Grams, Morgan E et al. (2017) APOL1 Risk Variants and Cardiovascular Disease: Results From the AASK (African American Study of Kidney Disease and Hypertension). Arterioscler Thromb Vasc Biol 37:1765-1769
Juraschek, Stephen P; Appel, Lawrence J; Miller 3rd, Edgar R (2017) Metoprolol Increases Uric Acid and Risk of Gout in African Americans With Chronic Kidney Disease Attributed to Hypertension. Am J Hypertens 30:871-875
Chen, Teresa K; Tin, Adrienne; Peralta, Carmen A et al. (2017) APOL1 Risk Variants, Incident Proteinuria, and Subsequent eGFR Decline in Blacks with Hypertension-Attributed CKD. Clin J Am Soc Nephrol 12:1771-1777

Showing the most recent 10 out of 1825 publications